title: Enzymatically hydrolyzed lactotripeptides do not lower blood pressure in mildly hypertensive subjects.
abstract: BACKGROUND
  Several placebo-controlled clinical studies suggest that products containing isoleucyl-prolyl-proline and valyl-prolyl-proline are able to lower blood pressure without adverse effects. The most efficient way of producing high concentrations of these lactotripeptides (LTPs) is enzymatic hydrolysis of dairy protein (casein) with the use of a mixture of several enzymes derived from the nongenetically modified organism Aspergillus oryzae, including proteases and peptidases. To date, no large studies of the blood pressure-lowering properties of enzymatically produced LTP (ELTP) powder in European populations have been published.
  
  
  OBJECTIVE
  This study was performed to evaluate the hypothesis that consumption of ELTP in a yogurt beverage for 8 wk significantly lowers blood pressure.
  
  
  METHODS
  In this multicenter, double-blind, parallel, placebo-controlled trial, office blood pressure was evaluated in 275 Dutch hypertensive subjects. Blood pressures and body weight were measured on several days at baseline and at weeks 4 and 8 of the intervention between 2.5 and 3 h after intake of the test product. Twenty-four-h urine samples were collected at baseline and at the end of the intervention for urinalysis of sodium, potassium, creatinine, and microalbumin excretion.
  
  
  RESULTS
  The results showed that 10.2 mg ELTP/d does not lead to a reduction in systolic blood pressure (P = 0.66) or diastolic blood pressure (P = 0.72) compared with placebo.
  
  
  CONCLUSIONS
  This study showed no effect of an ELTP-enriched yogurt beverage on blood pressure in hypertensive subjects in a fairly large study.
authors.affiliation: Unilever Food & Health Research Institute, Vlaardingen, Netherlands.
authors.forename: Kim
authors.initials: K
authors.lastname: van der Zander
authors.forename: Michiel L
authors.initials: ML
authors.lastname: Bots
authors.forename: Annette A A
authors.initials: AA
authors.lastname: Bak
authors.forename: Mettina M G
authors.initials: MM
authors.lastname: Koning
authors.forename: Peter W
authors.initials: PW
authors.lastname: de Leeuw
mesh_terms: D000328:Adult; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects*; D043302:Cultured Milk Products / Q000737:chemistry; D003971:Diastole; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006973:Hypertension / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009426:Netherlands; D009842:Oligopeptides / Q000494:pharmacology*; D010455:Peptides / Q000494:pharmacology*; D013599:Systole; D017211:Treatment Failure; D016482:Urinalysis; D015014:Yogurt
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D009842:Oligopeptides; D010455:Peptides; C489032:isoleucyl-prolyl-proline; C489031:valyl-prolyl-proline